What is Aequus Pharmaceuticals Inc. (AQSZF) stock price today?

Aequus Pharmaceuticals Inc. (AQSZF) is currently trading at $0.00.

What is AQSZF P/E ratio?

Aequus Pharmaceuticals Inc.'s P/E ratio is -1.52. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AQSZF return on equity (ROE)?

Aequus Pharmaceuticals Inc.'s return on equity (ROE) is 33.33%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Aequus Pharmaceuticals Inc.'s market cap?

Aequus Pharmaceuticals Inc. has a market capitalization of $159161.

OTC · Drug Manufacturers - Specialty & Generic

Aequus Pharmaceuticals Inc. (AQSZF) Stock

$0.00 OTC: AQSZF Healthcare

Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country.

Valuation

Metric	Value
Price	$0.00
Market Cap	$159161
P/E Ratio	-1.52
P/B Ratio	-0.10
P/S Ratio	0.17
EPS (TTM)	$-0.01
52-Week High	$0.01
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	33.33%
ROA	-68.07%
ROCE	3.87%
Gross Margin	56.95%
Operating Margin	-34.83%
Net Margin	-71.46%
Debt/Equity	-1.17
Current Ratio	0.03

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$3.0M	$3.0M	$1.0M	$0	$1.0M
Operating Profit	$-1.0M	$-2.0M	$-3.0M	$-3.0M	$-2.0M
Net Profit	$-1.0M	$-2.0M	$-3.0M	$-3.0M	$-2.0M
EPS	$-0.01	$-0.01	$-0.02	$-0.02	$-0.02
Op Margin	-30.1%	-59.2%	-187.2%	-1106.5%	-364.1%

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$3.0M	$4.0M	$2.0M	$1.0M	$1.0M
Total Liabilities	$3.0M	$3.0M	$3.0M	$5.0M	$7.0M
Cash	$2.0M	$2.0M	$0	$0	$0
Borrowings	$2.0M	$2.0M	$3.0M	$5.0M	$7.0M

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-1.0M	$-1.0M	$-2.0M	$-2.0M	$-2.0M
Investing Cash Flow	$0	$-1.0M	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$2.0M	$0
Net Cash Flow	$1.0M	$1.0M	$-2.0M	$0	$0
Free Cash Flow	$-1.0M	$-1.0M	$-2.0M	$-2.0M	$-2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-32.38
FCF Yield	-2.29%
Quick Ratio	0.03
Interest Coverage	-1.34
Return 1Y	-40.00%
Return 3Y	-96.55%
Return 5Y	-98.83%

Ownership

Insiders Held14.68%

Institutions Held0.00%

Institutions Float Held0.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACUSAcusphere, Inc.	$0.00	—	0.00	$49	0.00%
BIOAFBioasis Technologies Inc.	$0.00	—	-0.12	$7941	0.00%
DVLPGolden Developing Solutions, Inc.	$0.00	—	0.00	$1413	0.00%
HPMMHemp Naturals, Inc.	$0.00	—	0.00	$26426	0.00%
IVIXFInvion Limited	$0.04	+0.00%	-0.31	$4.03M	0.00%

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.

Aequus Pharmaceuticals Inc. (AQSZF) stock trades at $0.00 with a market capitalization of $159161. The stock is valued at a price-to-earnings (P/E) ratio of -1.52, price-to-book of -0.10, price-to-sales of 0.17. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, Aequus Pharmaceuticals Inc. generates a return on equity (ROE) of 33.33% — well above the market average, a sign of a high-quality business, return on capital employed of 3.87%, an operating margin of -34.83%, a net profit margin of -71.46%.

Official website: www.aequuspharma.ca

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides